The explanted inlay was returned to the manufacturer, and the investigation is underway.The device history record review of the manufacturing lot was performed and there were no discrepancies or unusual findings related to the reported issue.Corneal haze, decreased vision, and corneal scarring are listed in the device labeling as known potential risks.(b)(4).
|
The patient underwent implantation of the corneal inlay in the right eye on (b)(6) 2016.Early in the postoperative period, the patient presented with trace diffuse lamellar keratitis (dlk) and a few red blood cells in the interface that resulted from a hemorrhage during flap creation with the femtosecond laser.The patient was treated successfully with routine topical steroids and the event was not considered serious.It should be noted that celluvisc was used intraoperatively, which may have contributed to the dlk.At some time later in the postoperative period (exact date not known), the patient presented with corneal haze and the patient was treated with topical steroids.Approximately one year postoperatively, the patient presented with recurrent central corneal haze and decreased best corrected distance vision (bcdva) from 20/25+ (preoperatively) to 20/50.The inlay was explanted on (b)(6) 2017.The surgeon reports that a dlk-like inflammation was a contributing factor in the development of corneal haze.The source of the dlk was believed to be related to toxins in the sterile instrument case.At last examination on one-week post explant, the patient's bcdva was 20/50-1 with the presence of a mild scar and haze.Additional information will be requested.
|